Octavio Espinoza - 31 Dec 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Issuer symbol
LGND
Transactions as of
31 Dec 2025
Net transactions value
+$765
Form type
4
Filing time
06 Jan 2026, 19:21:16 UTC
Previous filing
18 Dec 2025
Next filing
18 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Espinoza Octavio Chief Financial Officer 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza 06 Jan 2026 0001905248

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Other $765 +8 +0.03% $95.68 28,575 31 Dec 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).